Key Points
- CEO insider sale: Marshall Fordyce sold 18,500 Vera Therapeutics shares for approximately $684,500, reducing his holdings by 7.29% to 235,244 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
- Stock and financial position: VERA opened at $34.27, with a market capitalization of about $2.47 billion and a 52-week range of $23.05 to $56.05. The company recently beat quarterly EPS estimates, reporting a loss of $1.52 per share versus the expected $1.58 loss.
- Analyst sentiment remains positive: Vera has a consensus “Moderate Buy” rating and an average price target of $80.15, supported by encouraging Phase 3 TRUTAKNA results, though investors remain focused on regulatory approval, commercialization and competition.
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer owned 235,244 shares of the company's stock, valued at approximately $8,704,028. The trade was a 7.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Fordyce also recently made the following trade(s):
- On Wednesday, September 2nd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $35.12, for a total value of $649,720.00.
- On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00.
- On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.93, for a total value of $701,705.00.
Vera Therapeutics Stock Performance
NASDAQ:VERA opened at $34.27 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. The business has a fifty day simple moving average of $34.43 and a two-hundred day simple moving average of $36.91. Vera Therapeutics, Inc. has a 1 year low of $23.05 and a 1 year high of $56.05. The company has a market capitalization of $2.47 billion, a P/E ratio of -5.85 and a beta of 0.96.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period in the prior year, the business earned ($1.20) earnings per share. On average, analysts expect that Vera Therapeutics, Inc. will post -6.44 earnings per share for the current year.
Institutional Trading of Vera Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Eversept Partners LP boosted its stake in Vera Therapeutics by 9.4% in the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company's stock worth $155,581,000 after purchasing an additional 264,468 shares during the period. Geode Capital Management LLC grew its holdings in Vera Therapeutics by 9.3% during the 4th quarter. Geode Capital Management LLC now owns 1,444,925 shares of the company's stock valued at $73,185,000 after buying an additional 123,350 shares in the last quarter. Armistice Capital LLC grew its holdings in Vera Therapeutics by 22.0% during the 4th quarter. Armistice Capital LLC now owns 653,796 shares of the company's stock valued at $33,108,000 after buying an additional 117,796 shares in the last quarter. First Turn Management LLC increased its position in shares of Vera Therapeutics by 69.7% during the fourth quarter. First Turn Management LLC now owns 601,774 shares of the company's stock valued at $30,474,000 after buying an additional 247,245 shares during the period. Finally, Braidwell LP increased its position in shares of Vera Therapeutics by 7.8% during the second quarter. Braidwell LP now owns 564,724 shares of the company's stock valued at $24,232,000 after buying an additional 40,900 shares during the period. 99.21% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts have commented on VERA shares. William Blair reaffirmed an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Raymond James Financial reiterated a "strong-buy" rating on shares of Vera Therapeutics in a research note on Tuesday. HC Wainwright lowered their price target on shares of Vera Therapeutics from $125.00 to $90.00 and set a "buy" rating on the stock in a research report on Wednesday, August 12th. Jefferies Financial Group restated a "buy" rating and set a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Bank of America raised their price objective on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $80.15.
Read Our Latest Research Report on VERA
Vera Therapeutics News Summary
Here are the key news stories impacting Vera Therapeutics this week:
- Positive Sentiment: Phase 3 success supports approval hopes: Vera said TRUTAKNA met all primary and secondary endpoints in the ORIGIN 3 trial. The results showed sustained kidney protection over two years and a reduction in the decline of kidney function, strengthening the case for full approval in IgAN. Vera Therapeutics says TRUTAKNA met all Phase III endpoints
- Positive Sentiment: Commercial opportunity is improving: The favorable ORIGIN 3 data could position TRUTAKNA for broader use in IgAN and intensify competition with other kidney-disease treatments, including products developed by Otsuka. Investors viewed the durable efficacy and kidney-function benefits as important differentiators. Vera’s strong Phase 3 IgAN data intensify kidney disease rivalry
- Neutral Sentiment: Investors remain focused on execution: Positive trial results have increased expectations for regulatory approval and eventual commercialization, but some commentary remains cautious about approval timing, launch execution and competition. Vera Therapeutics: Why I’m sticking with Hold despite positive TRUTAKNA data
- Negative Sentiment: CEO reduced his holdings: CEO Marshall Fordyce sold 18,500 shares for approximately $684,500, reducing his ownership by 7.29%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which limits its usefulness as a signal about management’s current outlook, but insider selling may still weigh modestly on sentiment. Vera Therapeutics CEO Form 4 filing
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company's research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.
Vera's leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
